Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05863351

Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study

Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)

Sponsor: ECOG-ACRIN Cancer Research Group

Conditions Metastatic Renal Cell Carcinoma Stage IV Renal Cell Cancer AJCC v8

Interventions Computed Tomography Magnetic Resonance Imaging Questionnaire Administration Stereotactic Ablative Radiotherapy Systemic Therapy

Updated 15 times since 2023 Last updated: Feb 27, 2026 Started: Sep 7, 2023 Primary completion: Dec 1, 2030 Completion: Aug 1, 2037

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Metastatic Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v8, this trial is ongoing. The trial is conducted by ECOG-ACRIN Cancer Research Group and has accumulated 15 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

15 versions recorded

Mar 2026 — Present [monthly]

Active Not Recruiting PHASE3
Feb 2026 — Mar 2026 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE3
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE3
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE3

▶ Show 10 earlier versions

Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE3
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE3
Nov 2024 — Sep 2025 [monthly]

Recruiting PHASE3
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE3
May 2024 — Jun 2024 [monthly]

Recruiting PHASE3
Apr 2024 — May 2024 [monthly]

Recruiting PHASE3
Nov 2023 — Apr 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jun 2023 — Nov 2023 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Data source: Eastern Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ames, United States , Ankeny, United States , Ann Arbor, United States , Aurora, United States , Baltimore, United States , Birmingham, United States , Bismarck, United States , Bloomington, United States , Bozeman, United States , Brighton, United States and 69 more locations